文献速递关节外科

全髋关节置换术前与术后启动血栓预防的临床结局相似:一项基于登记研究

Similar Clinical Outcomes with Preoperative and Postoperative Start of Thromboprophylaxis in THA: A Register-based Study.
PubMed 文献 · Clin Orthop Relat Res · 2017-06-22

该研究基于挪威关节置换登记库和全国患者登记库,纳入2008年1月1日至2011年12月31日期间因原发性全髋关节置换术(THA)的25,163例患者,比较术前与术后启动低分子肝素(LMWH)预防的临床效果。经多因素logistic回归校正后,两组在出血事件、血栓栓塞事件及术后其他临床并发症方面无重大差异,但术前组再入院率更高。作者认为术后启动LMWH可降低成本、减少与椎管内麻醉相关的风险并便于当日入院。

要点

  • 在25,163例THA患者中,术前与术后启动LMWH预防在出血事件和血栓栓塞事件方面无重大差异。
  • 术前启动LMWH组的再入院率高于术后启动组(OR 0.92;95% CI 0.85-0.97;p=0.016)。
  • 术后启动LMWH可降低成本、减少椎管内麻醉相关风险并便于当日入院。

核心结论

  • 无论THA术前还是术后启动LMWH预防,术后并发症风险似乎相当。
  • 术后启动方式可降低成本、减少椎管内麻醉相关风险并便于当日入院。
  • 包括实验室检查在内的个体化风险评估方法将是可行的。

研究设计与样本

  • 基于人群的随访设计,采用国际健康编码的预设数据,评估THA术前或术后启动LMWH预防的临床效果。
  • 数据来源于挪威关节置换登记库和全国患者登记库,限定为2008年1月1日至2011年12月31日在挪威实施的原发性THA。
  • 两个登记库通过11位个人识别号(社会保障号)识别患者后合并。
  • 获取了人口学、行政和手术细节以及术后180天内预防相关事件的数据。
  • 共纳入25,163例THA患者进行分析,其中9,977例(40%)接受术前LMWH,15,186例(60%)接受术后LMWH。

主要发现

  • 校正年龄、性别、手术时间、手术年份和美国麻醉医师学会(ASA)分级后,两组出血事件无重大差异(OR 1.04;95% CI 0.88-1.22;p=0.660)。
  • 校正后两组血栓栓塞事件无重大差异(OR 1.03;95% CI 0.84-1.27;p=0.786)。
  • 校正后两组其他术后临床并发症无重大差异(OR 0.86;95% CI 0.76-0.99;p=0.034)。
  • 校正后6个月死亡率相似(OR 0.76;95% CI 0.56-1.05;p=0.093)。
  • 校正后再入院率在术前组更高(OR 0.92;95% CI 0.85-0.97;p=0.016)。

临床怎么用

  • 作者认为,术后启动LMWH可降低成本、减少椎管内麻醉相关风险并便于当日入院。
  • 作者认为,包括实验室检查在内的个体化风险评估方法将是可行的。

局限性

  • 证据等级为III级,治疗性研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Elective THA is associated with a high risk of thromboembolic events. Although these events may be less common now than they were in the past, they can be serious, and most patients undergoing the procedure therefore still receive thromboprophylaxis. However, controversy remains regarding whether to begin thromboprophylaxis before THA or after to best balance the risks of clotting and bleeding. QUESTIONS/PURPOSES: We asked the following questions: (1) Is there a difference in bleeding events with pre- versus postoperative thromboprophylaxis? (2) Is there a difference in thromboembolic episodes after THA between the two regimens? (3) How do the two approaches of thromboprophylaxis influence mortality, readmissions, and other complications? METHODS: We used a population-based followup design with predefined data based on international health codification to assess clinical effects of LMWH prophylaxis initiated before or after THA. We took data limited to primary THAs done in Norway between January 1, 2008, and December 31, 2011, from the Norwegian Arthroplasty Register and the National Patient Register to have necessary data elements to complete the study. The two registers were merged after identifying patients with their 11-digit personal identification number (Social Security number). We obtained data regarding demographics, administrative and surgical details, and episode histories for prophylaxis-related events within 180 days of surgery. A total of 25,163 patients undergoing THA were included for analysis, and 9977(40%) versus 15,186 (60%) patients received pre- and postoperative LMWH, respectively. We performed statistical adjustment for differences in baseline characteristics using multivariate logistic regression. RESULTS: After adjustment for age, sex, operation time, year of surgery, and American Society of Anesthesiologists class, we could not show major differences in bleeding events; (odds ratio [OR], 1.04; 95% CI, 0.88-1.22; p = 0.660), thromboembolic episodes; (OR, 1.03; 95% CI, 0.84-1.27; p = 0.786), or other postoperative clinical complications; (OR, 0.86; 95% CI, 0.76-0.99; p = 0.034), with the two regimens. Six-month mortality was similar, (OR, 0.76; 95% CI, 0.56-1.05; p = 0.093), and the readmission rate was higher in the preoperative group; (OR, 0.92; 95% CI, 0.85-0.97; p = 0.016). CONCLUSIONS: The risk for postoperative complications seems to be comparable whether LMWH prophylaxis is initiated before or after THA. The postoperative approach reduces costs, decreases risks related to neuraxial anesthesia, and facilitates same-day admissions. Methods for individual risk assessment including laboratory tests would be feasible. LEVEL OF EVIDENCE: Level III, therapeutic study.

来源:Clin Orthop Relat Res,查看原文。版权归原作者所有。

引用

  1. Borgen PO, Pripp AH, Dybvik E, et al. Similar Clinical Outcomes with Preoperative and Postoperative Start of Thromboprophylaxis in THA: A Register-based Study. Clin Orthop Relat Res. 2017. PMID: 28643079. doi:10.1007/s11999-017-5419-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。